Payment & Shipping Terms:
|Name:||Prostaglandin E1 ,Alprostadil||CAS:||745-65-3|
|Packing:||1kg/Bag,10kg/Drum,25kg/Drum Or As Required||MF:||C20H33O5|
Prostaglandin E1 Powder,
C20H34O5 Alprostadil Powder
Product name: Alprostadil
English name: Prostaglandin E1
Chinese aliases: PGE1; Alprostadil; Column gland E1; (1 r, 2 r, 3 r) - 3 - hydroxy - 2 - [(E) - (3 s) - 3 - hydroxy - 1 - octene base] - 5 - oxygen generation cyclopentane heptanoic acid; The front room
CAS No. : 745-65-3
Molecular formula: C20H33O5
Molecular weight: 353.4736
Properties: white needle crystal, soluble in ethanol, slightly soluble in water.
Melting point: 112-118 ° C
Than the curl: 58-64
|Product Name||Prostaglandin E1|
|Appearance||White or almost white powder|
Prostaglandin E1 PGE1 exerts a number of effects, including systemic vasodilation, inhibition of platelet aggregation, and stimulation of intestinal motility. PGE1 relaxes isolated smooth muscle cells contracted by norepinephrine. It has become widely used in the treatment of ED. Alprostadil binds with PGE receptors and results in a cyclic adenosine monophosphate (cAMP) mediated smooth muscle relaxation. Little is known about the pharmacokinetics of PGE1, but it is believed that as much as 80% is metabolized in one pass through the lungs. Such rapid degradation probably accounts for its lack of significant cardiovascular side effects when administered intracavernosally. PGE1 can also be metabolized in the penis.
1. Alprostadil is used in maintaining a patent ductus arteriosus in newborns.
2. Alprostadil is also as urethral suppositories and in injectable form.
3. Alprostadil is also used for critical limb ischemia.
This product is a medical intermediate, the preparation has the effect of inhibiting platelet aggregation, thrombosis A2 generation, atherosclerotic lipid plaque formation and immune complex, can dilate peripheral and coronary vessels, used for myocardial infarction, thromboangiitis, arteriosclerosis obliterans and other diseases.
Usage: suitable for myocardial infarction, heart failure, thromboangiitis, chronic arterial occlusion, retinal central vein thrombosis, etc
Contact Person: July